Redeye provides an update following Mindark’s Q2 2025 report.
Redeye argues that the relatively disappointing quarterly figures increase the likelihood of the sha...
Redeye has updated its estimates and valuation following Heliospectra’s Q2 2025 report.
Redeye is positive about Kardium’s FDA approval for the Globe system, which allows the commercial ph...
VBG Group redovisade ett fortsatt svagt andra kvartal med lägre omsättning och marginaler, men vi se...
* The strong focus on profitability continues * '25e-'27e adj.
Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective...
Following a rights issue that was 61% oversubscribed, BeammWave has completed a subsequent directed ...
ChargePanel tecknade i juni avtal med fordonsleasingsbolaget Arval, som är ett dotterbolag till stor...
Redeye is only making minor changes to our forecasts following the Q2 report and other recent events...
Taaleri will host its CMD tomorrow on Tuesday 2nd of September.
Redeye return with an updated view following Nekkar’s Q2 figures that posted mixed figures during a ...
Redeye is only making very small adjustments to our forecasts on the back of Systemair’s Q1 report.
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-li...
Redeye comments on Binero IT’s H1-25 results, which presented mixed figures.
Redeye is not surprised by the announced directed share issue of SEK6m.
Redeye comments on Binero Group's H1-25 results, which presented mixed figures.
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-lin...
Redeye provides an update following Jumpgate’s Q1 2025 report.
Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase ...
